

CITATION REPORT

List of articles citing

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

DOI: 10.1016/s2213-2600(14)70041-4

Lancet Respiratory Medicine, the, 2014, 2, 395-404.

Source: <https://exaly.com/paper-pdf/58740731/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
474	Predictors of viral pneumonia in patients with community-acquired pneumonia. <i>PLoS ONE</i> , 2014 , 9, e114370	3.70	10
473	Tamiflu report comes under fire. 2014 , 508, 439-40		13
472	Seasonal influenza: Controversies, conundrums and consensus. 2014 , 9, 428-433		
471	References. 2014 , 175-189		
470	Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. <i>Clinical Infectious Diseases</i> , 2014 , 59, e172-85	11.6	66
469	Crystallography and New Medicines: Examples from Influenza and Cell Death. 2014 , 67, 1720		2
468	Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. <i>Clinical Infectious Diseases</i> , 2014 , 59, 774-82	11.6	37
467	Preventing ARDS: progress, promise, and pitfalls. <i>Chest</i> , 2014 , 146, 1102-1113	5.3	39
466	The safety of oseltamivir in pregnancy: an updated review of post-marketing data. 2014 , 23, 1035-42		14
465	Emerging respiratory infections: influenza, MERS-CoV, and extensively drug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 970-2	35.1	2
464	Do we need a replacement medication for influenza with good efficacy?. 2014 , 22, 84		
463	Infectious Diseases and the Kidney in Children. 2014 , 1-53		
462	Developments in the treatment of severe influenza: lessons from the pandemic of 2009 and new prospects for therapy. 2014 , 27, 560-5		13
461	Influenza. 2014 , 7, 616-623		
460	Cochrane column. 2014 , 43, 1691-6		1
459	Markers of prognosis specific to influenza infection: are we there yet?. 2014 , 189, 1159-60		3
458	Should we recommend neuroaminidase inhibitors for influenza?. 2014 , 20, O979-80		7

457	Effectiveness of neuraminidase inhibitors for severe influenza. <i>Lancet Respiratory Medicine,the</i> , 2014 , 2, 346-8	35.1	4
456	Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. <i>Lancet Respiratory Medicine,the</i> , 2014 , 2, e10	35.1	5
455	[Which samples to obtain in the emergency department for the microbiological diagnosis of community-acquired pneumonia in the immunocompetent patient?]. 2014 , 23, 490-497		
454	Seasonal Human Influenza: Treatment Options. 2014 , 6, 227-244		1
453	Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 1136-1149	25.5	72
452	Antiviral combinations for severe influenza. <i>Lancet Infectious Diseases, The</i> , 2014 , 14, 1259-70	25.5	127
451	Antimicrobial treatment of non-cystic fibrosis bronchiectasis. 2014 , 12, 1277-96		25
450	Neuraminidase inhibitors for influenza complications--Authors' reply. 2014 , 384, 1261-2		1
449	Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. <i>Lancet Respiratory Medicine,the</i> , 2014 , 2, e10-2	35.1	6
448	Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. <i>Lancet Respiratory Medicine,the</i> , 2014 , 2, e8-9	35.1	8
447	Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. <i>Lancet Respiratory Medicine,the</i> , 2014 , 2, e9-e10	35.1	9
446	The public health policy implications of understanding metabiosis. 2014 , 16, 3-4		3
445	2009 H1N1 influenza and pregnancy--5 years later. <i>New England Journal of Medicine</i> , 2014 , 371, 1373-5	59.2	19
444	Neuraminidase inhibitors for influenza complications. 2014 , 384, 1260-1		3
443	Oseltamivir use amongst hospitalized patients infected with influenza. <i>Influenza and Other Respiratory Viruses</i> , 2014 , 8, 547-8	5.6	5
442	Antivirals for influenza: where now for clinical practice and pandemic preparedness?. 2014 , 384, 386-7		10
441	Response to Al-Husayni and Hassoun. 2014 , 61, 176-7		
440	Influenza Outbreaks Among Passengers and Crew on Two Cruise Ships: A Recent Account of Preparedness and Response to an Ever-Present Challenge. 2015 , 22, 306-11		25

439	Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons, 2010/11-2012/13. 2015 , 15, 573		15
438	Influenza Antiviral Expenditures and Outpatient Prescriptions in the United States, 2003-2012. 2015 , 35, 991-7		2
437	Why do we need systematic reviews to inform healthcare decisions in the disaster context. 2015 , 8, 103-7		1
436	Antiviral Drugs for Influenza and Other Respiratory Virus Infections. 2015 , 531-545.e5		1
435	Aureonitol, a Fungi-Derived Tetrahydrofuran, Inhibits Influenza Replication by Targeting Its Surface Glycoprotein Hemagglutinin. <i>PLoS ONE</i> , 2015 , 10, e0139236	3.7	16
434	Immune Responses in Acute and Convalescent Patients with Mild, Moderate and Severe Disease during the 2009 Influenza Pandemic in Norway. <i>PLoS ONE</i> , 2015 , 10, e0143281	3.7	17
433	Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. <i>Clinical Infectious Diseases</i> , 2015 , 60, 1677-80	11.6	15
432	Prognostic factors for mortality in patients hospitalized with influenza complications, in Taiwan. 2015 , 7, 73-5		5
431	Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. 2015 , 45, 1642-52		70
430	Use of neuraminidase inhibitors for prophylaxis and treatment of pandemic influenza: summary of a Faculty of Public Health meeting. 2016 , 38, e580-e586		
429	Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. 2015 , 59, 1569-82		126
428	Influenza: the rational use of oseltamivir. 2015 , 385, 1700-1702		18
427	Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. 2015 , 385, 1729-1737		351
426	The Enigma ML FluAB-RSV assay: a fully automated molecular test for the rapid detection of influenza A, B and respiratory syncytial viruses in respiratory specimens. 2015 , 15, 23-32		18
425	Optimizing antiviral therapy for influenza: understanding the evidence. 2015 , 13, 417-25		16
424	Advancing treatment options for influenza: challenges with the human influenza challenge. <i>Journal of Infectious Diseases</i> , 2015 , 211, 1033-5	7	5
423	Respiratory Infections in the U.S. Military: Recent Experience and Control. 2015 , 28, 743-800		52
422	A decade of individual participant data meta-analyses: A review of current practice. 2015 , 45, 76-83		69

421	On neuraminidase inhibitors and evidence-based medicine. 2015 , 21, 214-6		
420	Host genes and influenza pathogenesis in humans: an emerging paradigm. 2015 , 14, 7-15		19
419	Oseltamivir reduces clinical illness in households in Bangladesh. <i>Lancet Infectious Diseases, The</i> , 2015 , 15, 617-9	25.5	
418	Point-of-care testing for respiratory viruses in adults: The current landscape and future potential. 2015 , 71, 501-10		47
417	Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis. 2015 , 21, 956-63		53
416	Crossing the scale from within-host infection dynamics to between-host transmission fitness: a discussion of current assumptions and knowledge. 2015 , 370,		63
415	Attitudes and perceptions among the pediatric health care providers toward influenza vaccination in Qatar: A cross-sectional study. 2015 , 33, 3821-8		18
414	Rates and effectiveness of antiviral use among hospitalized influenza patients. 2015 , 13, 835-42		1
413	Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. 2015 , 47, 808-19		7
412	The Tamiflu fiasco and lessons learnt. 2015 , 47, 11-6		23
411	Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain. 2015 , 39, 222-33		5
410	MBRRACE-UK: saving lives, improving mothers' care - implications for anaesthetists. 2015 , 24, 161-73		31
409	Neuraminidase inhibitors for influenza: fully evaluating benefits and harms. <i>Lancet Respiratory Medicine, the</i> , 2015 , 3, e7-8	35.1	2
408	Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain. 2015 , 39, 222-233		
407	Roche perspectives on Tamiflu. 2015 , 21, 226-9		3
406	Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States. <i>Journal of Infectious Diseases</i> , 2015 , 212, 1200-8	7	47
405	Challenges and opportunities in developing respiratory syncytial virus therapeutics. <i>Journal of Infectious Diseases</i> , 2015 , 211 Suppl 1, S1-S20	7	85
404	Emerging respiratory tract viral infections. 2015 , 21, 284-92		21

403	Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic. <i>Clinical Infectious Diseases</i> , 2015 , 60 Suppl 1, S30-41	11.6	10
402	Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives. 2015 , 13, 1361-72		5
401	Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management. <i>Influenza and Other Respiratory Viruses</i> , 2015 , 9, 20-31	5.6	14
400	Influenza and Other Respiratory Viruses. From the Editor's desk. <i>Influenza and Other Respiratory Viruses</i> , 2015 , 9, 99-100	5.6	2
399	Community-acquired pneumonia. 2015 , 386, 1097-108		267
398	Peramivir: evidence to support the use of the first approved intravenous therapy for influenza. 2015 , 10, 937-948		4
397	Randomized Trials and Observational Studies: The Current Philosophical Controversy. 2015 , 1-11		
396	Update in Viral Infections 2014. 2015 , 192, 676-81		3
395	Neuraminidase inhibitors: who, when, where?. 2015 , 21, 222-5		36
394	Avian influenza: recent epidemiology, travel-related risk, and management. 2015 , 17, 456		5
393	Influenza Virus. 2016 , 1009-1058		0
392	Antiviral Medications in Seasonal and Pandemic Influenza. 2016 , 113, 799-807		20
391	Influenza SIRS with Minimal Pneumonitis. 2016 , 3, 37		1
390	Dual Acting Neuraminidase Inhibitors Open New Opportunities to Disrupt the Lethal Synergism between <i>Streptococcus pneumoniae</i> and Influenza Virus. 2016 , 7, 357		31
389	Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data. <i>PLoS ONE</i> , 2016 , 11, e0160430	3.7	13
388	Assessing the State of Knowledge Regarding the Effectiveness of Interventions to Contain Pandemic Influenza Transmission: A Systematic Review and Narrative Synthesis. <i>PLoS ONE</i> , 2016 , 11, e0168262	3.7	12
387	Twitter Influence on UK Vaccination and Antiviral Uptake during the 2009 H1N1 Pandemic. 2016 , 4, 26		39
386	Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza. 2016 , 22, 949-55		35

385	Influenza Neuraminidase Inhibitors: Synthetic Approaches, Derivatives and Biological Activity. 2016 , 21,			38
384	Susceptibility of influenza viruses circulating in Western Saudi Arabia to neuraminidase inhibitors. 2016 , 37, 461-5			3
383	The neuraminidase inhibitors evidence of harms - in context. 2016 , 48, 661-2			2
382	Influenza A and methicillin-resistant Staphylococcus aureus co-infection in rhesus macaques - A model of severe pneumonia. 2016 , 129, 120-129			17
381	Impact of HIV on the severity of influenza. 2016 , 10, 463-472			7
380	Antiviral therapies on the horizon for influenza. 2016 , 30, 106-115			50
379	Pulmonary changes in Norwegian fatal cases of pandemic influenza H1N1 (2009) infection: a morphologic and molecular genetic study. <i>Influenza and Other Respiratory Viruses</i> , 2016 , 10, 525-531	5.6		11
378	Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors. 2016 , 2, 710-714			12
377	Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: A drug-use investigation in patients with high risk factors. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 677-84	2.2		8
376	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2016 , 10, 192-204	5.6		46
375	ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation. <i>Influenza and Other Respiratory Viruses</i> , 2016 , 10, 152-3	5.6		7
374	Severe community-acquired pneumonia: timely management measures in the first 24 hours. 2016 , 20, 237			31
373	Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis. 2016 , 60, 6679-6691			57
372	Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers. 2016 , 60, 5437-44			24
371	Bayesian uncertainty quantification for transmissibility of influenza, norovirus and Ebola using information geometry. 2016 , 13,			11
370	A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama. 2016 , 133, 85-94			14
369	Viral load is strongly associated with length of stay in adults hospitalised with viral acute respiratory illness. 2016 , 73, 598-606			14
368	Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors. 2016 , 80, 43-49			6

367	Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: a systematic review of observational studies with meta-analysis. 2016 , 48, 813-22	50
366	Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients. 2016 , 19, 1185-1215	16
365	Quick Evidence Synopsis. 2016 , 30, 1071-1075	
364	Quick Evidence Synopsis. 2016 , 30, 1077-1083	
363	Influenza. 2016 , 355, i6258	71
362	Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. 2017 , 22, 313-323	7
361	Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context. 2016 , 16, 552	10
360	Predictors of influenza among older adults in the emergency department. 2016 , 16, 615	31
359	Modernising epidemic science: enabling patient-centred research during epidemics. 2016 , 14, 212	31
358	Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclox, and gemcitabine. 2016 , 126, 69-80	13
357	Current and novel antiviral strategies for influenza infection. 2016 , 18, 126-34	38
356	Infectious Diseases and the Kidney in Children. 2016 , 1609-1654	2
355	Transparency and trust in the European pharmaceutical sector: a Commentary. 2016 , 19, 1120-1128	2
354	Influenza Vaccination and Antiviral Therapy in Pregnant Women. <i>Journal of Infectious Diseases</i> , 2016 , 214, 505-6	7 2
353	Respiratory Viral Testing and Influenza Antiviral Prescriptions During Hospitalization for Acute Respiratory Illnesses. 2016 , 3, ofv216	7
352	Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses. 2016 , 129, 21-38	41
351	The PARADIGM of Influenza Vaccination in Heart Failure Patients. 2016 , 4, 159-161	4
350	The Recognition and Management of Maternal Sepsis. 2016 , 215-236	

349	Osetamivir for influenza infection in children: risks and benefits. 2016 , 10, 79-87		16
348	An integrated algorithm for performance optimization of neurosurgical ICUs. 2016 , 43, 142-153		10
347	Immunological considerations for developing antibody therapeutics for Influenza A. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 474-7	4.4	10
346	Pharmacokinetics of Oral and Intravenous Osetamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. 2017 , 42, 155-164		7
345	Intravenous zanamivir or oral osetamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 135-146	35.1	63
344	Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada. 2017 , 140, 158-163		4
343	Barriers and strategies to improve influenza vaccination in Pakistan. 2017 , 10, 881-883		12
342	Survival biases lead to flawed conclusions in observational treatment studies of influenza patients. 2017 , 84, 121-129		21
341	Interdisciplinary pharmacometrics linking osetamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. 2017 , 83, 1580-1594		28
340	Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15. 2017 , 72, 1556-1573		13
339	Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies. 2017 , 38, 295-305		7
338	Outpatient antibiotic stewardship: Interventions and opportunities. 2017 , 57, 464-473		42
337	Pulmonary infections in the returned traveller. 2017 , 9, 1		12
336	Additional molecular testing of saliva specimens improves the detection of respiratory viruses. 2017 , 6, e49		73
335	Multiplex Respiratory Virus Testing for Antimicrobial Stewardship: A Prospective Assessment of Antimicrobial Use and Clinical Outcomes Among Hospitalized Adults. <i>Journal of Infectious Diseases</i> , 2017 , 216, 936-944	7	47
334	Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1328-1334	11.6	48
333	Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 401-411	35.1	160
332	Reducing diagnostic uncertainty to improve treatment of respiratory infections. <i>Lancet Respiratory Medicine</i> , 2017 , 5, 364-365	35.1	2

331	Influenza-Associated Aspergillosis in Critically Ill Patients. 2017 , 196, 524-527		127
330	Influence of time to diagnosis of severe influenza on antibiotic use, length of stay, isolation precautions, and mortality: a retrospective study. <i>Influenza and Other Respiratory Viruses</i> , 2017 , 11, 337-344	5.6	17
329	Influenza. 2017 , 390, 697-708		369
328	Oseltamivir Use Among Children and Adults Hospitalized With Community-Acquired Pneumonia. 2017 , 4, ofw254		2
327	Randomized Trials and Observational Studies: The Current Philosophical Controversy. 2017 , 873-886		0
326	Pandemic and Avian Influenza A Viruses in Humans: Epidemiology, Virology, Clinical Characteristics, and Treatment Strategy. 2017 , 38, 59-70		39
325	Antiviral Treatments. 2017 , 38, 139-153		45
324	Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains. 2017 , 7, 12336		10
323	Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection. 2017 , 494, 298-304		13
322	New options to treat influenza B. 2017 , 2, 1342-1343		
321	Decision-making Process by Users and Providers of Health Care Services During the AH1N1 Epidemic Influenza in Mexico: Lessons Learned and Challenges Ahead. 2017 , 48, 276-283		
320	Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. 2017 , 72, 2990-3007		53
319	Antiviral Drugs for the Treatment and Prevention of Influenza. 2017 , 9, 318-332		6
318	Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. 2017 , 7, 9409		69
317	Influenza. <i>Annals of Internal Medicine</i> , 2017 , 167, ITC33-ITC48	8	40
316	A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region. 2017 , 22, 1300-1312		20
315	Influenza in long-term care facilities. <i>Influenza and Other Respiratory Viruses</i> , 2017 , 11, 356-366	5.6	67
314	Early administration of neuraminidase inhibitors in adult patients hospitalized for influenza does not benefit survival: a retrospective cohort study. 2017 , 36, 1673-1677		5

313	Systems-based approach to examine the cytokine responses in primary mouse lung macrophages infected with low pathogenic avian Influenza virus circulating in South East Asia. 2017 , 18, 420		2
312	The pharmacological management of severe influenza infection - 'existing and emerging therapies'. 2017 , 10, 81-95		14
311	Increased Antiviral Treatment Among Hospitalized Children and Adults With Laboratory-Confirmed Influenza, 2010-2015. <i>Clinical Infectious Diseases</i> , 2017 , 64, 364-367	11.6	23
310	Use of Neuraminidase Inhibitors for Treatment of Severe Influenza: Times Are Changing. <i>Clinical Infectious Diseases</i> , 2017 , 64, 368-369	11.6	4
309	Antiviral Agents Against Respiratory Viruses. 2017 , 1318-1326.e2		4
308	Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions. 2017 , 20, 819-827		27
307	Increased incidence of co-infection in critically ill patients with influenza. 2017 , 43, 48-58		109
306	The effect of statins on influenza-like illness morbidity and mortality. 2017 , 26, 63-70		13
305	Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. <i>Chest</i> , 2017 , 151, 1069-1080	5.3	81
304	Efficacy and Safety of Intravenous Peramivir Compared With Oseltamivir in High-Risk Patients Infected With Influenza A and B Viruses: A Multicenter Randomized Controlled Study. 2017 , 4, ofx129		22
303	A Case of Influenza A (H3N2) Complicated by Community-Acquired Pneumonia and Death in a Young Healthy Adult during the 2013-2014 Season. 2017 , 5, 1		90
302	Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use. 2017 , 17, 671		62
301	Risk of mortality associated with respiratory syncytial virus and influenza infection in adults. 2017 , 17, 785		45
300	Viral Infections, an Overview with a Focus on Prevention of Transmission. 2017 , 368-377		2
299	Markers of Disease Severity in Patients with Spanish Influenza in the Japanese Armed Forces, 1919-1920. 2017 , 23, 662-664		0
298	South African guideline for the management of community-acquired pneumonia in adults. 2017 , 9, 1469-1502		33
297	Effectiveness of antiviral treatment in preventing death in severe hospitalised influenza cases over six seasons. 2018 , 146, 799-808		16
296	Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1708-1717	7	64

295	A Randomized Study Evaluating the Effectiveness of Oseltamivir Initiated at the Time of Hospital Admission in Adults Hospitalized With Influenza-Associated Lower Respiratory Tract Infections. <i>Clinical Infectious Diseases</i> , 2018 , 67, 736-742	11.6	17
294	Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and health economics. 2018 , 146, 496-507		8
293	Pulmonary Diseases in Refugees and Migrants in Europe. 2018 , 95, 273-286		2
292	Influenza Viruses. 2018 , 1181-1190.e5		2
291	The impact of influenza virus infection in pregnancy. 2018 , 13, 263-274		27
290	Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan. 2018 , 16, 173-182		16
289	The role of adjuvant immunomodulatory agents for treatment of severe influenza. 2018 , 150, 202-216		64
288	Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1492-1500	11.6	74
287	Oseltamivir Treatment of Influenza in Children. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1501-1503	11.6	19
286	Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus. <i>Journal of Infectious Diseases</i> , 2018 , 217, 887-896	7	24
285	Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice. 2018 , 90, 1431-1437		3
284	Antiviral treatment of childhood influenza: an update. 2018 , 30, 438-447		11
283	Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. 2018 , 14, 356-359		29
282	Clinician-initiated research on treating the host response to pandemic influenza. <i>Human Vaccines and Immunotherapeutics</i> , 2018 , 14, 790-795	4.4	19
281	Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1054-1060	11.6	21
280	Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis. 2018 , 44, 257-260		12
279	Comparison of the three waves of avian influenza A(H7N9) virus circulation since live poultry markets were permanently closed in the main urban areas in Zhejiang Province, July 2014-June 2017. <i>Influenza and Other Respiratory Viruses</i> , 2018 , 12, 259-266	5.6	10
278	Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study. 2018 , 37, 319-323		4

277	Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. 2018 , 12, 1320-1360	81
276	Pandemic 2009 influenza A (H1N1)-associated deaths among children in China: A retrospective analysis. 2018 , 2, 166-171	1
275	Possible association of influenza A infection and reverse takotsubo syndrome. 2018 , 11,	6
274	Treatment of influenza with neuraminidase inhibitors. 2018 , 31, 514-519	12
273	ACOG Committee Opinion No. 753: Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza. 2018 , 132, e169-e173	10
272	Oseltamivir in pregnancy and birth outcomes. 2018 , 18, 519	9
271	Effectiveness of an educational intervention to improve antibiotic dispensing practices for acute respiratory illness among drug sellers in pharmacies, a pilot study in Bangladesh. 2018 , 18, 676	14
270	Bronchiectasis in children: diagnosis and treatment. 2018 , 392, 866-879	100
269	Treatment and prophylaxis of influenza. 2018 , 61, 49	0
268	[Flu virus and respiratory virus infections]. 2018 , 12, 3291-3297	1
267	Influenza. 2018 , 4, 3	437
266	Gaps in the Clinical Management of Influenza: A Century Since the 1918 Pandemic. 2018 , 320, 755-756	7
265	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. 2018 , 23, 185-199	2
264	Advancements in Host-Based Interventions for Influenza Treatment. 2018 , 9, 1547	18
263	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. 2018 , 44, 1470-1482	76
262	Outbreaks of influenza-like illness in care homes in the East of England: impact of variations in neuraminidase inhibitor provision. <i>Public Health</i> , 2018 , 162, 98-103	4 2
261	Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza. 2018 , 18, 311	2
260	Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice. 2018 , 163, 2349-2358	8

259	Improving Influenza Testing and Treatment in Hospitalized Children. 2018 , 8, 570-577		3
258	Readiness for Responding to a Severe Pandemic 100 Years After 1918. 2018 , 187, 2596-2602		31
257	Contemporary management of severe influenza disease in the intensive care unit. 2018 , 48, 48-55		3
256	Severe morbidity among hospitalised adults with acute influenza and other respiratory infections: 2014-2015 and 2015-2016. 2018 , 146, 1350-1358		15
255	Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness. 2019 , 41, 379-390		3
254	Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. 2019 , 25, 372-378		108
253	Concomitant severe influenza and cryptococcal infections: A case report and literature review. 2019 , 98, e15544		4
252	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020 , 221, 356-366	7	10
251	Influenza Antiviral Prescribing Practices and the Influence of Rapid Testing Among Primary Care Providers in the US, 2009-2016. 2019 , 6, ofz192		9
250	Influenza: overview on prevention and therapy. 2019 , 42, 51-55		5
249	Impact of a PCR point of care test for influenza A/B on an acute medical unit in a large UK teaching hospital: results of an observational, pre and post intervention study. 2019 , 8, 120		9
248	Antivirals targeting the polymerase complex of influenza viruses. 2019 , 169, 104545		82
247	Intensive care management of influenza-associated pulmonary aspergillosis. 2019 , 25, 1501-1509		32
246	Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. 2019 , 54,		16
245	Seasonal Influenza and Avian Influenza A(H5N1) Virus Surveillance among Inpatients and Outpatients, East Jakarta, Indonesia, 2011-2014. 2019 , 25, 2031-2039		
244	Use of prophylactic antivirals and care home characteristics associated with influenza in care homes with confirmed outbreaks. <i>Public Health</i> , 2019 , 177, 48-56	4	1
243	[Influenza infection: An update for clinicians]. 2019 , 40, 158-165		1
242	[Influenza]. 2019 , 60, 1127-1135		8

241	Recommendations for Prevention and Control of Influenza in Children, 2019-2020. 2019 , 144,		32
240	Influenza [Jeder kennt die Grippe]und doch wird sie immer noch unterschätzt. 2019 , 16, 215-231		0
239	Is there a clinical difference between influenza A and B virus infections in hospitalized patients? : Results after routine polymerase chain reaction point-of-care testing in the emergency room from 2017/2018. 2019 , 131, 362-368		5
238	Partnering for enhanced digital surveillance of influenza-like disease and the effect of antivirals and vaccines (PEDSIDEA). <i>Influenza and Other Respiratory Viruses</i> , 2019 , 13, 309-318	5.6	11
237	Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses. 2019 , 93,		11
236	Oseltamivir for the treatment of influenza in children and adolescents. 2019 , 90, 317.e1-317.e8		0
235	Influenza virus-related critical illness: prevention, diagnosis, treatment. 2019 , 23, 214		79
234	Drugs for Influenza Treatment: Is There Significant News?. 2019 , 6, 109		31
233	Effectiveness of the Neuraminidase Inhibitors: The Supporting Evidence Increases. <i>Journal of Infectious Diseases</i> , 2020 , 221, 340-342	7	3
232	Managing seasonal influenza in hospitalized patients - without an influenza point-of-care test. <i>Journal of Hospital Infection</i> , 2019 , 102, 471-473	6.9	
231	Antiviral Therapy for the Next Influenza Pandemic. 2019 , 4,		15
230	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. <i>Clinical Infectious Diseases</i> , 2019 , 68, 895-902	11.6	165
229	Evaluation of nasal levels of interferon and clinical severity of influenza in children. 2019 , 114, 37-42		6
228	Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus. <i>Journal of Infection and Chemotherapy</i> , 2019 , 25, 578-583	2.2	9
227	Epidemiology, Diagnosis, Treatment, and Prevention of Influenza Infection in Oncology Patients. 2019 , 15, 177-184		18
226	[Oseltamivir for the treatment of influenza in children and adolescents]. 2019 , 90, 317.e1-317.e8		1
225	Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1896-1902	11.6	21
224	An Overview of the Most Significant Zoonotic Viral Pathogens Transmitted from Animal to Human in Saudi Arabia. 2019 , 8,		5

223	Severe acute respiratory distress syndrome (ARDS) induced by human adenovirus B21: Report on 2 cases and literature review. 2019 , 51, 99-104		10
222	Influenza-like illness and antimicrobial prescribing in Australian general practice from 2015 to 2017: a national longitudinal study using the MedicineInsight dataset. 2019 , 9, e026396		10
221	Pragmatic multicentre randomised controlled trial evaluating the impact of a routine molecular point-of-care 'test-and-treat' strategy for influenza in adults hospitalised with acute respiratory illness (FluPOC): trial protocol. 2019 , 9, e031674		2
220	A novel framework for evaluating the impact of individual decision-making on public health outcomes and its potential application to study antiviral treatment collection during an influenza pandemic. <i>PLoS ONE</i> , 2019 , 14, e0223946	3.7	2
219	Clinical Characteristics and Prognosis of Influenza B Virus-Related Hospitalizations in Northern China during the 2017-18 Influenza Season: A Multicenter Case Series. 2019 , 2019, 8756563		3
218	Clinical Significance of Upper Airway Virus Detection in Critically Ill Hematology Patients. 2019 , 199, 518-528		24
217	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. <i>Clinical Infectious Diseases</i> , 2019 , 68, e1-e47	11.6	245
216	Clinical Impact of Rapid Point-of-Care PCR Influenza Testing in an Urgent Care Setting: a Single-Center Study. 2019 , 57,		25
215	Community-acquired bacterial co-infection predicts severity and mortality in influenza-associated pneumonia admitted patients. <i>Journal of Infection and Chemotherapy</i> , 2019 , 25, 129-136	2.2	16
214	Inhibiting Viral Polymerase and Neuraminidase in Treating Influenza. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1013-1015	7	3
213	Impact of multiplex molecular assay turn-around-time on antibiotic utilization and clinical management of hospitalized children with acute respiratory tract infections. 2019 , 110, 11-16		18
212	Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. 2019 , 74, 654-662		49
211	Beyond Members of the Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication. 2019 , 63,		53
210	Implementation of influenza point-of-care testing and patient cohorting during a high-incidence season: a retrospective analysis of impact on infection prevention and control and clinical outcomes. <i>Journal of Hospital Infection</i> , 2019 , 101, 276-284	6.9	28
209	Risk factors for hospitalization of patients with chikungunya virus infection at sentinel hospitals in Puerto Rico. 2019 , 13, e0007084		11
208	Analysis of acute respiratory infections due to influenza virus A, B and RSV during an influenza epidemic 2018. 2019 , 47, 425-433		17
207	Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes. <i>Clinical Infectious Diseases</i> , 2019 , 69, 52-58	11.6	47
206	Facilitating Early Treatment of Influenza in Hospitals: Empiric Antivirals or Empiric Diagnostics?. <i>Clinical Infectious Diseases</i> , 2019 , 69, 59-60	11.6	

205	Oseltamivir Resistance in Severe Influenza A(H1N1)pdm09 Pneumonia and Acute Respiratory Distress Syndrome: A French Multicenter Observational Cohort Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1089-1091	11.6	13
204	Resistance of Influenza Virus to Antiviral Medications. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1092-1094	11.6	5
203	Influenza and tuberculosis co-infection: A systematic review. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 77-91	5.6	22
202	Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 226-235 ⁶	5.6	6
201	Severe flu management: a point of view. 2020 , 46, 153-162		15
200	A community-based survey on influenza and vaccination knowledge, perceptions and practices in Peru. 2020 , 38, 1194-1201		11
199	Rapid syndromic molecular testing in pneumonia: The current landscape and future potential. 2020 , 80, 1-7		20
198	Recommended hospital preparations for future cases and outbreaks of novel influenza viruses. 2020 , 14, 41-50		5
197	Intrahospital mortality of influenza patients during the 2017-2018 influenza season : Report from a tertiary care hospital in Austria. 2020 , 132, 176-181		4
196	Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 1192-1200	35.1	63
195	Neuraminidase characterisation reveals very low levels of antiviral resistance and the presence of mutations associated with reduced antibody effectiveness in the Irish influenza 2018/2019 season. 2020 , 132, 104653		
194	Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection. 2020 , 56, 106155		7
193	Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. <i>New England Journal of Medicine</i> , 2020 , 383, 1645-1656	59.2	38
192	Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults : A Cross-sectional Study. <i>Annals of Internal Medicine</i> , 2020 , 173, 605-613	8	35
191	14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activity. 2020 , 181, 104885		7
190	The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study. 2020 , 20, 628		3
189	Analysis of pressure-driven membrane preconcentration for point-of-care assays. 2020 , 14, 054101		1
188	Clinical characteristics and outcomes of influenza A and B virus infection in adult Australian hospitalised patients. 2020 , 20, 913		3

187	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. 2020 , 7, 596587		7
186	Outcome of Patients Admitted to Intensive Care Units due to Influenza-Related Severe Acute Respiratory Illness in 2017-2018 Flu Season: A Multicenter Study from Turkey. 2020 , 99, 954-960		0
185	Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. 2020 , 8,		2
184	Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. 2020 , 8,		2
183	Reply. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1579		7
182	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. 2020 , 158, 104899		118
181	Synthetic Advancement of Neuraminidase Inhibitor Tamiflu 2020 , 5, 6083-6122		3
180	Development of an Ordinal Scale Treatment Endpoint for Adults Hospitalized With Influenza. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4369-e4374	11.6	2
179	Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza. 2020 , 4, 176-182		5
178	A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 1787-1799	59.2	3303
177	Pay attention to SARS-CoV-2 infection in children. 2020 , 4, 1-4		15
176	Baloxavir Marboxil: A Review in Acute Uncomplicated Influenza. 2020 , 80, 1109-1118		14
175	COVID-19 Clinical Trials: Unraveling a Methodological Gordian Knot. 2020 , 202, 635-637		7
174	Post-influenza aspergillus ventriculitis. 2020 , 7-8, 100026		4
173	Critical care management of adults with community-acquired severe respiratory viral infection. 2020 , 46, 315-328		134
172	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2020 , 26, 880-894		23
171	Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials. 2020 , 37, 2646-2666		3
170	Respiratory and Nonrespiratory Diagnoses Associated With Influenza in Hospitalized Adults. 2020 , 3, e201323		15

169	Influenza management with new therapies. 2020 , 26, 215-221		3
168	Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan. 2020 , 39, 1637-1640		4
167	Effect of antiviral treatment in older patients hospitalized with confirmed influenza. 2020 , 178, 104785		0
166	Seasonal and pandemic influenza: 100 years of progress, still much to learn. 2020 , 13, 566-573		25
165	Clinical manifestations and risk factors for mortality of patients with severe influenza during the 2016-2018 season. 2020 , 95, 347-351		8
164	Methodological challenges of analysing COVID-19 data during the pandemic. 2020 , 20, 81		38
163	Severity and outcomes of influenza-related pneumonia in type A and B strains in China, 2013-2019. 2020 , 9, 42		5
162	Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission. 2020 , 16, e1008395		15
161	Association Between the Use of Antibiotics, Antivirals, and Hospitalizations Among Patients With Laboratory-confirmed Influenza. <i>Clinical Infectious Diseases</i> , 2021 , 72, 566-573	11.6	4
160	Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. 2021 , 11,		9
159	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59		1
158	Initiation of Oseltamivir in Critically Ill Patients: Variations in Prescribing Practices. 2021 , 55, 265-266		1
157	Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza. 2021 , 55, 760-771		4
156	Clinical usefulness of a rapid molecular assay, ID NOW™ influenza A & B 2, in adults. <i>Journal of Infection and Chemotherapy</i> , 2021 , 27, 450-454	2.2	1
155	Clinical impact of a routine, molecular, point-of-care, test-and-treat strategy for influenza in adults admitted to hospital (FluPOC): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 419-429	35.1	6
154	Predictors and Outcomes of Hospitalization for Influenza: Real-World Evidence from the United States Medicare Population. 2021 , 10, 213-228		1
153	Influenza and COVID-19: What does co-existence mean?. <i>Influenza and Other Respiratory Viruses</i> , 2021 , 15, 407-412	5.6	24
152	Low rate of oseltamivir prescription among adults and children with confirmed influenza illness in France during the 2018-19 influenza season. 2021 , 76, 1057-1062		0

151	Management of Influenza Virus Infections (Orthomyxoviridae). 2021 , 160-174	
150	Etiology of Severe Acute Respiratory Infections, Bangladesh, 2017. 2021 , 27, 324-326	
149	From COVID-19 to the Common Cold: Novel Host-Targeted, Pan-Respiratory Antiviral Small Molecule Therapeutics.. 2021 ,	4
148	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. 2021 , 7,	4
147	Useful clinical findings and simple laboratory data for the diagnosis of seasonal influenza. 2021 , 22, 231-236	1
146	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. 2021 , 16, 165-183	
145	Update in Viral Infections in the Intensive Care Unit. 2021 , 8, 575580	3
144	Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection. 2021 , 11, 580679	3
143	Xpert Xpress Flu/RSV: Validation and impact evaluation at a large UK hospital trust. 2021 , 93, 5146-5151	2
142	Optimizing antiviral treatment for seasonal influenza in the USA: a mathematical modeling analysis. 2021 , 19, 54	1
141	Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalized patients. 2021 , 104, 232-238	2
140	Targeting tumour necrosis factor to ameliorate viral pneumonia. 2021 ,	4
139	Clinical Effectiveness and Safety of Antivirals for Influenza in Pregnancy. 2021 , 8, ofab138	2
138	Comparison of clinical characteristics and outcomes between respiratory syncytial virus and influenza-related pneumonia in China from 2013 to 2019. 2021 , 40, 1633-1643	0
137	Comparing intravenous peramivir with oral oseltamivir for patients with influenza: a meta-analysis of randomized controlled trials. 2021 , 19, 1039-1046	0
136	Use of point-of-care testing for respiratory viruses in hospital. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 324-326	35.1 0
135	Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials. 2021 , 86, 54-65	2
134	Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice. 2021 , 9,	4

133	Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. 2021 , 19, 425-441		47
132	Changes in characteristics and case-severity in patients hospitalised with influenza A (H1N1) pdm09 infection between two epidemic waves-England, 2009-2010. <i>Influenza and Other Respiratory Viruses</i> , 2021 , 15, 599-607	5.6	1
131	Pyrrolidone and Caprolactam-Based Materials in Active Pharmaceutical Ingredient (API) Applications. 1839-1931		
130	[58/m-fever, cough and severe hypoxemia : Preparation for the medical specialist examination: part '65]. 2021 , 62, 435-439		
129	Neuraminidase inhibitor use in adults presenting to hospital with suspected influenza: A questionnaire-based survey of practice among hospital physicians. 2021 , 11, 100075		
128	[Management of Adult Community-Acquired Pneumonia and Prevention - Update 2021 - Guideline of the German Respiratory Society (DGP), the Paul-Ehrlich-Society for Chemotherapy (PEG), the German Society for Infectious Diseases (DGI), the German Society of Medical Intensive Care and Emergency Medicine (DGIM), the German Microbiological Society (DMG), the Competence Network CAPNETZ, the German College of General Practitioners and Family Physicians (DGEM), the German Society for Infectious Diseases (DGI), the German Society for Pneumology and Respiratory Therapy (DGPT)]		7
127	How COVID-19 will change the management of other respiratory viral infections. 2021 , 47, 1148-1151		
126	The role of influenza A virus-induced hypercytokinemia. 2021 , 1-17		3
125	Incidence and seasonality of respiratory viruses among medically attended children with acute respiratory infections in an Ecuador birth cohort, 2011-2014. <i>Influenza and Other Respiratory Viruses</i> , 2021 ,	5.6	1
124	Lower cognitive scores among toddlers in birth cohorts with acute respiratory illnesses, fevers, and laboratory-confirmed influenza. <i>Influenza and Other Respiratory Viruses</i> , 2021 ,	5.6	1
123	Recommendations for Prevention and Control of Influenza in Children, 2021-2022. 2021 , 148,		4
122	Influenza Antiviral Treatment and Length of Stay. 2021 , 148,		2
121	Antiviral Use in Canadian Children Hospitalized for Influenza. 2021 , 148,		1
120	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. 2021 , 194, 105158		5
119	Exploration of the 2,3-dihydroisoindole pharmacophore for inhibition of the influenza virus PA endonuclease. 2021 , 116, 105388		
118	Influenza Management During the COVID-19 Pandemic: A Review of Recent Innovations in Antiviral Therapy and Relevance to Primary Care Practice. 2021 , 5, 974-991		1
117	Challenges in Severe Influenza Pneumonia. 2022 , 350-361		
116	Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. 2021 , 12, 2493-2508		5

115	Antibiotika und Chemotherapeutika. 2016 , 273-292		1
114	Report disputes benefit of stockpiling Tamiflu.		4
113	Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. 2016 , 97, 1807-1817		29
112	Influenza Interaction with Cocirculating Pathogens, and Its Impact on Surveillance, Pathogenesis and Epidemic Profile: A Key Role for Mathematical Modeling.		1
111	Influenza, pandemics and SARS. 2019 , 393-399		2
110	Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. 2015 , 9, e0003846	124	
109	Evaluation of the Becton Dickinson Rapid Influenza Diagnostic Tests in Outpatients in Germany during Seven Influenza Seasons. <i>PLoS ONE</i> , 2015 , 10, e0127070	3-7	7
108	Within-Host Models of High and Low Pathogenic Influenza Virus Infections: The Role of Macrophages. <i>PLoS ONE</i> , 2016 , 11, e0150568	3-7	17
107	Epidemiology, Seasonality and Treatment of Hospitalized Adults and Adolescents with Influenza in Jingzhou, China, 2010-2012. <i>PLoS ONE</i> , 2016 , 11, e0150713	3-7	10
106	Oseltamivir Treatment for Children with Influenza-Like Illness in China: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2016 , 11, e0153664	3-7	4
105	Seasonal Influenza A H1N1pdm09 Virus and Severe Outcomes: A Reason for Broader Vaccination in Non-Elderly, At-Risk People. <i>PLoS ONE</i> , 2016 , 11, e0165711	3-7	18
104	Use of influenza antivirals in patients hospitalized in Hong Kong, 2000-2015. <i>PLoS ONE</i> , 2018 , 13, e0190306	306	2
103	Point-of-care diagnostic tests for influenza in the emergency department: A cost-effectiveness analysis in a high-risk population from a Canadian perspective. <i>PLoS ONE</i> , 2020 , 15, e0242255	3-7	1
102	Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling. 2018 , 14, e1006770		45
101	Saikosaponin A inhibits influenza A virus replication and lung immunopathology. 2015 , 6, 42541-56		34
100	Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. 2016 , 4, 421		84
99	Agathisflavone, a Biflavonoid from <i>Anacardium occidentale</i> L., Inhibits Influenza Virus Neuraminidase. 2020 , 20, 111-120		6
98	Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017. 2019 , 24,		5

97	Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic. 2015 , 3, 1-48		2
96	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. 2016 , 20, 1-242		60
95	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN). <i>Communicable Diseases Intelligence (2018)</i> , 2019 , 43,	1.9	7
94	Late diagnosis of influenza in adult patients during a seasonal outbreak. 2018 , 33, 391-396		8
93	Pandemic Influenza A H1N1 in Oman: Epidemiology, Clinical Features, and Outcome of Patients Admitted to Sultan Qaboos University Hospital in 2009. 2016 , 31, 290-7		8
92	Management of hospitalized influenza A patients during the season 2018/19 : Comparison of three medical departments and the effect on outcome and antibiotic usage. 2021 , 133, 1310		
91	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. 2021 , 49, e1063-e1143		131
90	Comparison of prone positioning and extracorporeal membrane oxygenation in acute respiratory distress syndrome: A multicenter cohort study and propensity-matched analysis. 2021 ,		0
89	Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. 2021 , 47, 1181-1247		199
88	16-jähriger Junge mit Husten, Malaise und Kurzatmigkeit. 2015 , 53-57		
87	Viral Infections, an Overview with a Focus on Prevention of Transmission. 2016 ,		
86	Influenza. 2016 , 67, 353-361		
85	Antirespiratory Virus Agents. 271-290		
84	Update on influenza antiviral drug treatment and prophylaxis for the 2015-2016 influenza season. 2016 , 1, 1-4		
83	Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage. 2016 , 5, 2293		4
82	Antibiotika und Chemotherapeutika. 2017 , 271-290		
81	Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage. 2016 , 5, 2293		4
80	Open Questions. 2017 , 114, 269		

79	Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequela.		1
78	EARLY IDENTIFICATION OF SWINE INFLUENZA A (H1N1)- BASING ONEPIDEMIOLOGIC CLUE, CLINICAL PRESENTATION, IMAGING FINDINGS, PERIPHERAL LEUCOCYTE COUNTS AND SPO2 LEVELS. 2017 , 4, 5163-5166		
77	Antibiotika und antibakterielle Chemotherapeutika. 2018 , 325-343		
76	Neuraminidase inhibitors ¶s it time to call it a day?.		
75	Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication.		1
74	Therapeutic Approach for Seasonal Influenza and Pandemic.		0
73	Antibiotika und antibakterielle Chemotherapeutika. 2019 , 435-459		
72	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN). <i>Communicable Diseases Intelligence (2018)</i> , 2019 , 43,	1.9	3
71	Pandemic planning and critical care. 2019 , 259-276		
70	Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015-2016. <i>Influenza and Other Respiratory Viruses</i> , 2021 ,	5.6	1
69	Antibiotika und Antiinfektiva. 2020 , 307-330		
68	INFEKTIONSKRANKHEITEN. 2020 , pL1-pL16.2-10		
67	Influenza. <i>Annals of Internal Medicine</i> , 2021 , 174, ITC161-ITC176	8	0
66	Severe community-acquired pneumonia. 101-116		
65	Interpandemic (seasonal) influenza. 35-64		
64	Avian influenza: H7N9, H5N1 and other novel strains. 65-83		
63	Critical Care Considerations in Adult Patients With Influenza-Induced ARDS. <i>Critical Care Nurse</i> , 2020 , 40, 15-24	1.6	
62	Factors associated with influenza-like illness in care homes in Cheshire and Merseyside during the 2017-2018 influenza season. <i>Public Health</i> , 2020 , 187, 89-96	4	1

61	Point-of-care influenza testing impacts clinical decision, patient flow and length of stay in hospitalized adults. <i>Journal of Infectious Diseases</i> , 2020 ,	7	1
60	Antiviral medications for influenza. <i>Canadian Family Physician</i> , 2015 , 61, 351	0.9	3
59	A Narrative Review of Influenza: A Seasonal and Pandemic Disease. <i>Iranian Journal of Medical Sciences</i> , 2017 , 42, 2-13	1.2	39
58	A literature review of severity scores for adults with influenza or community-acquired pneumonia - implications for influenza vaccines and therapeutics. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-15	4.4	1
57	Clinical Characteristics and Outcomes of Influenza-Associated Pulmonary Aspergillosis Among Critically Ill Patients: A Systematic Review and Meta-Analysis. <i>Journal of Hospital Infection</i> , 2021 ,	6.9	1
56	Antiviral Drugs Against Influenza Virus. <i>Methods and Principles in Medicinal Chemistry</i> , 2022 , 59-96	0.4	
55	Role of etiotropic therapy in the treatment and prevention of influenza complications amidst the COVID-19 pandemic. <i>Meditsinskiy Sovet</i> , 2021 , 86-93	0.4	
54	Antibiotika und Antiinfektiva. 2021 , 207-229		
53	Delayed Influenza Treatment in Children With False-Negative Rapid Antigen Test: A Retrospective Single-Center Study in Korea 2016-2019.. <i>Journal of Korean Medical Science</i> , 2022 , 37, e3	4.7	
52	Severe influenza: is there a role for antiviral combinations?. <i>Lancet Infectious Diseases, The</i> , 2022 ,	25.5	
51	Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.. <i>Lancet Infectious Diseases, The</i> , 2022 ,	25.5	1
50	When COVID rules Severe acute respiratory illness due to another virus. <i>Journal of Advanced Lung Health</i> , 2022 , 2, 22		
49	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	120
48	Influenza Testing and Treatment among Patients Hospitalized with Community-Acquired Pneumonia.. <i>Chest</i> , 2022 ,	5.3	0
47	Severe Infections Due to Respiratory Viruses.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022 , 43, 60-74	3.9	0
46	Suppression of SARS-CoV-2 Infection by Existing Kampo Formulas and Crude Constituent Drugs Used for Treatment of Common Cold Respiratory Symptoms.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 804103	5.6	0
45	Laninamivir-induced ischemic enterocolitis: A case report.. <i>World Journal of Clinical Cases</i> , 2022 , 10, 2864-2870	4.28	1
44	Laninamivir-induced ischemic enterocolitis: A case report. <i>World Journal of Clinical Cases</i> , 2022 , 10, 2862-2868		

43	Antiviral Drugs in Influenza.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,	4.6	5
42	Evaluation of the Clinical Effectiveness of Oseltamivir for Influenza Treatment in Children.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 849545	5.6	0
41	Management of Severe Influenza.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021 , 42, 771-787	3.9	
40	Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis.. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 8,	5.6	1
39	Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia.. <i>PLoS ONE</i> , 2021 , 16, e0261411	3.7	0
38	Guía de práctica clínica para el manejo de la neumonía adquirida en la comunidad. <i>Revista Facultad De Medicina</i> , 2021 , 70, e93814	0.4	
37	Comparison of hospitalized COVID-19 and influenza patients requiring supplemental oxygen in a cohort study: clinical impact and resource consumption.. <i>Clinical Infectious Diseases</i> , 2022 ,	11.6	1
36	Clinical manifestations of hospitalized influenza patients without risk factors: A prospective multicenter cohort study in Japan via internet surveillance.. <i>Journal of Infection and Chemotherapy</i> , 2022 ,	2.2	
35	Is combination antiviral therapy for influenza the optimal approach?. <i>Lancet Infectious Diseases</i> , 2022 , 22, 587-588	25.5	0
34	Low Levels of Procalcitonin Are Related to Decreased Antibiotic Use in Children Hospitalized Due to Influenza. <i>Diagnostics</i> , 2022 , 12, 1148	3.8	1
33	Macrophages undergo necroptosis during severe influenza A infection and contribute to virus-associated cytokine storm.		
32	Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection. <i>Journal of Infection and Chemotherapy</i> , 2022 ,	2.2	0
31	Impact of influenza infection on the short- and long-term health of patients with chronic obstructive pulmonary disease. <i>Journal of Medical Economics</i> , 1-29	2.4	
30	Guideline Concordant Antiviral Treatment in Children at High-risk for Influenza Complications. <i>Clinical Infectious Diseases</i> ,	11.6	
29	Severe influenza A in a Tunisian ICU sentinel SARI centre: Epidemiological and clinical features. <i>PLoS ONE</i> , 2022 , 17, e0270814	3.7	
28	Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
27	If the Test Fits: Diagnosis to Aid in the Treatment of Influenza. 2022 ,		
26	Influenza. 2022 , 400, 693-706		6

25	Synthesis and Neuraminidase Inhibitory Activity of Sialic Acid Analogues with Fluoro, Phosphono, and Sulfo Functionalities. 2022 , 303-320	0
24	Recent Increases in Influenza-Related Hospitalizations, Critical Care Resource Use, and In-Hospital Mortality: A 10-Year Population-Based Study in South Korea. 2022 , 11, 4911	0
23	Association of Early Oseltamivir With Improved Outcomes in Hospitalized Children With Influenza, 2007-2020.	0
22	Recommendations for Prevention and Control of Influenza in Children, 2022-2023. 2022 , 150,	0
21	Developing and validating clinical features-based machine learning algorithms to predict influenza infection in influenza-like illness patients. 2022 ,	0
20	16-jähriger Junge mit Husten, Malaise und Kurzatmigkeit. 2022 , 53-58	0
19	Comparison of oseltamivir and Galactosylceramide for reducing disease and transmission in pigs infected with 2009 H1N1 pandemic influenza virus. 9,	0
18	Respiratory viruses: their importance and lessons learned from COVID-19. 2022 , 31, 220051	1
17	Sialidase Inhibitors with Different Mechanisms. 2022 , 65, 13574-13593	0
16	Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients.	1
15	Management of Unique Pneumonias Seen in the Intensive Care Unit. 2022 , 36, 825-837	0
14	A systematic review of acute and emergency care interventions for adolescents and adults with severe acute respiratory infections including COVID-19 in low- and middle-income countries. 12,	0
13	Influenza Viruses. 2023 , 1205-1213.e5	0
12	Influenza antivirals and their role in pandemic preparedness. 2022 , 105499	1
11	Rocking Pneumonia and the Boogie Woogie Flu. 48-54	0
10	Successful Treatment of Complicated Influenza A(H3N2) Virus Infection and Rhabdomyolysis with Compassionate Use of IV Zanamivir. 2023 , 16, 85	0
9	Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. 2023 , 11, 200	0
8	Antiviral therapies for influenza. Publish Ahead of Print,	0

- 7 Comparison of the relative efficacy of β -lactam/ β -lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study. ○
- 6 Platelet Abnormalities in Children with Laboratory-Confirmed Influenza. **2023**, 13, 634 ○
- 5 CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF INFLUENZA IN CHILDREN RESIDING IN THE ASTRAKHAN REGION. **2022**, 24, 523-531 ○
- 4 Influenza. **2023**, 1-11 ○
- 3 ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. ○
- 2 ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. **2023**, 61, 2200735 ○
- 1 Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. ○